Evogene Ltd. (TLV: EVGN)

Market Cap	34.76M
Revenue (ttm)	35.58M
Net Income (ttm)	-74.80M
Shares Out	5.37M
EPS (ttm)	-14.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,260
Open	647.80
Previous Close	647.80
Day's Range	642.10 - 696.10
52-Week Range	641.00 - 3,700.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 17, 2024

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Huma...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 142
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: EVGN

Financial Performance

In 2023, Evogene's revenue was $5.64 million, an increase of 236.72% compared to the previous year's $1.68 million. Losses were -$23.88 million, -10.36% less than in 2022.

Financial numbers in USD